16 April 2021>: Original Paper
Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial
Arman Faravardeh 1DE* , Sanjeev Akkina 2DE , Rafael Villicana 3DE , Giselle Guerra 4DE , Misbah A. Moten 5ADE , Ulf Meier-Kriesche 5ADE , Daniel R. Stevens 5ACDE , Samir J. Patel 5DE , Suphamai Bunnapradist 6DEDOI: 10.12659/AOT.929535
Ann Transplant 2021; 26:e929535
Table 2 Rates of treatment failure at 12 months.
Outcome | Switched to LCPT | Remained on IR-Tac | P-value* |
---|---|---|---|
N=26 | N=29 | ||
Composite treatment failure, n (%) | 1 (4) | 1 (3) | 1.0000 |
Treatment failure due to: | |||
BPAR n (%) | 1 (4) | 0 | 0.4727 |
Death, n (%) | 0 | 0 | – |
Graft failure, n (%) | 0 | 0 | – |
Lost to follow up, n (%) | 0 | 1 (3) | 1.0000 |
BPAR – biopsy-proven acute rejection; IR-Tac – immediate-release tacrolimus; LCPT – LCP-tacrolimus. * P values were calculated by Fisher’s exact test. |